| Light-driven post-translational installation of reactive protein side chains B Josephson, C Fehl, PG Isenegger, S Nadal, TH Wright, AWJ Poh, ... Nature 585 (7826), 530-537, 2020 | 131 | 2020 |
| Synthesis, structural characterisation and antiproliferative activity of a new fluorescent 4-amino-1, 8-naphthalimide Tröger's base–Ru (ii)–curcumin organometallic conjugate S Shanmugaraju, B la Cour Poulsen, T Arisa, D Umadevi, HL Dalton, ... Chemical Communications 54 (33), 4120-4123, 2018 | 39 | 2018 |
| PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics Y Zeng, O Arisa, CJ Peer, A Fojo, WD Figg Seminars in Oncology, 2023 | 16 | 2023 |
| Phase I study and cell-free DNA analysis of T-DM1 and metronomic temozolomide for secondary prevention of HER2-positive breast cancer brain metastases S Jenkins, W Zhang, SM Steinberg, D Nousome, N Houston, X Wu, ... Clinical Cancer Research 29 (8), 1450-1459, 2023 | 14 | 2023 |
| Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma C Melani, R Lakhotia, S Pittaluga, JD Phelan, DW Huang, G Wright, ... New England Journal of Medicine 390 (23), 2143-2155, 2024 | 9 | 2024 |
| In Silico Re‐Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure–Response Simulation CJ Peer, KT Schmidt, O Arisa, WJ Richardson, K Paydary, DA Goldstein, ... The Journal of Clinical Pharmacology 63 (6), 672-680, 2023 | 7 | 2023 |
| Phase Ib/II study of multi-targeted therapy with venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory (R/R) diffuse large B-cell … C Melani, R Lakhotia, S Pittaluga, JD Phelan, G Wright, J Simard, ... Blood 142, 434, 2023 | 5 | 2023 |
| Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma M Hultcrantz, H Hassoun, N Korde, K Maclachlan, S Mailankody, D Patel, ... Blood Cancer Journal 14 (1), 164, 2024 | | 2024 |
| Simulating extended dosing intervals for atezolizumab: A comparative analysis between NONMEM and Pumas F Bateman, O Arisa, NC Cabanas, Y Zeng, C Peer, K Schmidt, WD Figg Cancer Research 84 (6_Supplement), 7184-7184, 2024 | | 2024 |
| Pharmacogenomic Variation May Impact Cyclophosphamide Metabolism and Graft Status after HCT for Sickle Cell Disease Y Zeng, O Arisa, CJ Peer, T Sissung, WD Figg, CD Fitzhugh, E Limerick Transplantation and Cellular Therapy, Official Publication of the American …, 2024 | | 2024 |
| Photoredox protein modification PG Isenegger, BG Davis, B Josephson, V Gouverneur, C Fehl, AWJ Poh, ... US Patent App. 18/005,519, 2023 | | 2023 |
| Determination of metarrestin (ML-246) in human plasma for a first-in-human clinical pharmacokinetic application by a simple and efficient uHPLC-MS/MS assay WJ Richardson, SM Zimmerman, A Reno, NC Cabanas, O Arisa, ... Journal of Chromatography B 1224, 123738, 2023 | | 2023 |
| Utilisation of enzymes as powerful tools towards fluorinated biomolecules OT Arisa University of Oxford, 2021 | | 2021 |
